Key Points
- Insider Pamela Cramer sold 3,350 Rhythm Pharmaceuticals shares on Dec. 11 at an average price of $111 for about $371,850, leaving her with 20,814 shares (a 13.86% reduction).
- Rhythm reported quarterly EPS of ($0.82), missing the ($0.72) estimate despite slightly higher-than-expected revenue, and continues to show deeply negative profitability (negative ROE ~433% and negative net margin ~110%).
- Analyst sentiment is generally positive with a MarketBeat consensus of "Moderate Buy" and a $124.27 price target, while several firms have raised targets into the $142–$150 range.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) insider Pamela Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the transaction, the insider owned 20,814 shares of the company's stock, valued at approximately $2,310,354. This trade represents a 13.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.
Rhythm Pharmaceuticals Stock Performance
NASDAQ RYTM opened at $112.52 on Tuesday. The business's 50 day moving average price is $105.60 and its 200-day moving average price is $92.84. Rhythm Pharmaceuticals, Inc. has a fifty-two week low of $45.90 and a fifty-two week high of $122.20. The company has a market cap of $7.51 billion, a P/E ratio of -36.30 and a beta of 1.96.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.10). The company had revenue of $51.30 million during the quarter, compared to the consensus estimate of $50.71 million. Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%. As a group, equities analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.32 EPS for the current year.
Wall Street Analyst Weigh In
RYTM has been the subject of a number of recent analyst reports. JMP Securities lifted their price target on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a "market outperform" rating in a research note on Thursday, September 25th. Morgan Stanley reiterated an "overweight" rating and issued a $150.00 price target on shares of Rhythm Pharmaceuticals in a report on Thursday. Oppenheimer downgraded Rhythm Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Wednesday, November 5th. Needham & Company LLC lifted their target price on Rhythm Pharmaceuticals from $120.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, December 11th. Finally, Cowen restated a "buy" rating on shares of Rhythm Pharmaceuticals in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Rhythm Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $124.27.
View Our Latest Stock Analysis on RYTM
Hedge Funds Weigh In On Rhythm Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in RYTM. PNC Financial Services Group Inc. raised its holdings in shares of Rhythm Pharmaceuticals by 1,386.2% in the first quarter. PNC Financial Services Group Inc. now owns 4,518 shares of the company's stock valued at $239,000 after acquiring an additional 4,214 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Rhythm Pharmaceuticals by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 445,429 shares of the company's stock valued at $23,594,000 after purchasing an additional 5,179 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Rhythm Pharmaceuticals in the 1st quarter worth approximately $7,803,000. Russell Investments Group Ltd. boosted its stake in shares of Rhythm Pharmaceuticals by 11,412.3% during the first quarter. Russell Investments Group Ltd. now owns 114,778 shares of the company's stock valued at $6,080,000 after purchasing an additional 113,781 shares in the last quarter. Finally, Aberdeen Group plc boosted its stake in shares of Rhythm Pharmaceuticals by 34.3% during the first quarter. Aberdeen Group plc now owns 108,129 shares of the company's stock valued at $5,728,000 after purchasing an additional 27,612 shares in the last quarter.
Rhythm Pharmaceuticals Company Profile
(
Get Free Report)
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
